MEQUON, Wis.–(BUSINESS WIRE)–Titan Spine announced the appointment of Paul Slosar, MD to the newly created position of Medical Director. Dr. Slosar is an accomplished, board certified spine surgeon who currently serves as President of SpineCare Medical Group in San Francisco, Medical Co-Director of the Spine Care Institute of San Francisco, Assistant Director of both Surgical Fellowship and Surgical Research for the San Francisco Spine Institute, and Member of the Board of Directors of the American Board of Spinal Surgery.
“We are extremely pleased Dr. Slosar accepted the position as Medical Director for Titan Spine. His reputation is exceptional,” said Kevin Gemas, President of Titan Spine. “Over the past two years, Dr. Slosar has provided our team with a unique perspective and has demonstrated a broad range of knowledge within the field of spinal fusion. Our board members and I believe his expertise and contributions will enhance our overall service and support to the medical community as well as help expedite the expansion of our bioactive interbody device portfolio.”
Dr. Slosar has served on Titan Spine’s Scientific Advisory Board and moderated several of the company’s physician training meetings. “The technology that Titan Spine brings to the interbody fusion surgeon is outstanding. The fact that the surface of their implant rapidly integrates with the vertebral endplate is unlike anything else I have used in the past,” said Dr. Slosar. “I believe the time is right for spine surgeons to require more out of their interbody implants. Most other implants function only as spacers while the Titan Spine implants actually participate in the fusion process via osseos integration. I am very excited about this opportunity and look forward to assisting Titan Spine as they provide spine surgeons with a comprehensive product line of interbody implant options.”
Titan Spine recently launched its Endoskeleton® TT interbody fusion device in July and continues to expand upon its product offerings of bioactive implants for spinal fusion. The company’s success is based upon a unique implant surface, large windows for radiographic visualization and autograft bone packing, and simple surgical techniques.
